In POAG an overexpression of CCN2/CTGF tips this balance towards TGF-β accompanied with an attenuation of BMP signaling in the trabecular meshwork, whether this can be prevented by new therapeutic drugs like the Rho kinase inhibitors will be the topic of future studies. The gene discussed is CCN2; the disease is open-angle glaucoma.